Gut Microbiota Changes in Patients with Bipolar Depression

作者：Shaohua Hu, Ang Li, Tingting Huang, Jianbo Lai, Jingjing Li, M. Elizabeth Sublette, Haifeng Lu, Qiaoqiao Lu, Yanli Du, Zhiying Hu, Chee H. Ng, Hua Zhang, Jing Lü, Tingting Mou, Shaojia Lu, Dandan Wang, Jinfeng Duan, Jianbo Hu, Manli Huang, Ning Wei, Weihua Zhou, Liemin Ruan, Ming D. Li, Yi Xu · 发表于：Advanced Science · 年份：2019 · DOI：10.1002/advs.201900752 · 被引用次数：177 · 研究领域：Tryptophan and brain disorders、Bipolar Disorder and Treatment、Gut microbiota and health

Abstract This study aims to characterize the gut microbiota in depressed patients with bipolar disorder (BD) compared with healthy controls (HCs), to examine the effects of quetiapine treatment on the microbiota, and to explore the potential of microbiota as a biomarker for BD diagnosis and treatment outcome. Analysis of 16S‐ribosomal RNA gene sequences reveals that gut microbial composition and diversity are significantly different between BD patients and HCs. Phylum Bacteroidetes and Firmicutes are the predominant bacterial communities in BD patients and HCs, respectively. Lower levels of butyrate‐producing bacteria are observed in untreated patients. Microbial composition changes following quetiapine treatment in BD patients. Notably, 30 microbial markers are identified on a random forest model and achieve an area under the curve (AUC) of 0.81 between untreated patients and HCs. Ten microbial markers are identified with the AUC of 0.93 between responder and nonresponder patients. This study characterizes the gut microbiota in BD and is the first to evaluate microbial changes following quetiapine monotherapy. Gut microbiota‐based biomarkers may be helpful in BD diagnosis and predicting treatment outcome, which need further validations.